放射線治療に関わるPET放射性薬剤の現状と展望

DOI Web Site
  • 吉本 光喜
    国立がん研究センター　先端医療開発センター　機能診断開発分野

書誌事項

タイトル別名
  • Current Status and Prospects on PET Radiopharmaceuticals for Radiotherapy
  • ホウシャセン チリョウ ニ カカワル PET ホウシャセイ ヤクザイ ノ ゲンジョウ ト テンボウ

この論文をさがす

抄録

18F-FDG is a most popular radiopharmaceutical for tumor diagnosis in the world. In addition, 11C-methionine, 18F-FLT and 11C-choline have been used to compensate for drawbacks of 18F-FDG. Now, novel radiopharmaceuticals are required to estimate or predict therapeutic efficacy because we have many strategies to treat tumors. Radiotherapy which damage DNA by producing free radicals is commonly used to treat various types of tumors. Hypoxia is closely associated with resistance to chemo- and/ or radiotherapy and is a common feature of solid tumors. Recently, understanding of tumor hypoxia in oncology has led to development of radiopharmaceuticals for hypoxia imaging. This review provides an overview of PET radiopharmaceuticals for hypoxia imaging and 18F-FBPA which is used for boron neutron capture therapy.

収録刊行物

  • 医学物理

    医学物理 35 (1), 10-15, 2015

    公益社団法人　 日本医学物理学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ